Ina Bisha
Ina Bisha has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Ali Saleh
Oncology Targeted Discovery-Drug CandidateDC, Chemistry, AstraZeneca, London E1 2AX, UK
17 shared publications - Alma Andoni
AstraZeneca, Gaithersburg, Maryland
17 shared publications - Ana De Almeida
AstraZeneca, Waltham, Massachusetts
17 shared publications - Benedicte Recolin
AstraZeneca, Cambridge, United Kingdom
17 shared publications - Christopher Ward
AstraZeneca, Gaithersburg, Maryland
17 shared publications - Claire Myers
AstraZeneca, Gaithersburg, Maryland
17 shared publications
Latest Publications
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Pharmacokinetic Parameters
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Pharmacokinetic Parameters
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 4]
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 4]
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 1]
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 1]
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Assessment of AZD5335/TOP1i-mediated DDR.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Assessment of AZD5335/TOP1i-mediated DDR.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Characterization of FRa mAb INT-019 (mAb49).
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Characterization of FRa mAb INT-019 (mAb49).
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 5]
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 5]
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335-related intra-tumoral pharmacodynamic analyses.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335-related intra-tumoral pharmacodynamic analyses.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Assessment of AZD5335-associated bystander activities.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Assessment of AZD5335-associated bystander activities.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 3]
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 3]